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Background: The prevalence of obesity and asthma has increased concurrently over the last
decades, suggesting a link between obesity and asthma. However, asthma might not be
adequately diagnosed in this population.
Aim: To investigate whether not only overdiagnosis but also underdiagnosis of asthma is pre-
sent in an obese population.
Methods: Morbidly obese subjects with or without physician-diagnosed asthma were recruited
from a pre-operative screening programme for bariatric surgery, and were characterized using
an extensive diagnostic algorithm.
Results: 473 subjects were screened; 220 met inclusion criteria, and 86 agreed to participate.
Among the 32 participating subjects who had a physician diagnosis of asthma, reversible airway
obstruction and/or bronchial hyperresponsiveness could only be detected in 19 patients (59%,uestionnaire; AQLQ, mini Asthma Quality of Life Questionnaire; BHR, bronchial hyperresponsiveness;
capacity; ERV, expiratory reserve volume; ESS, Epworth Sleepiness Scale; FEF25e75, Forced expiratory
Forced Vital Capacity; FeNO, Nitric Oxide; FEV1, forced expiratory volume in 1 s; FRC, functional
apacity; GERD, Gastro oesophageal reflux disease; ICS, inhaled corticosteroid; IOS, impulse oscill-
a syndrome; RV, residual volume; SPT, skin prick test; TLC, total lung capacity.
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Misdiagnosis of asthma 135795% CI [0.41e0.76]), whereas in 13 patients (41%, 95% CI [0.24e0.50]) the diagnosis of asthma
could not be confirmed (overdiagnosis). In contrast, in the remaining 54 patients, 17 (31%, 95%
CI [0.20e0.46]) were newly diagnosed with asthma (underdiagnosis).
Conclusion: Besides overdiagnosis, there is also substantial underdiagnosis of asthma in the
morbidly obese. Symptoms could be incorrectly ascribed to either obesity or asthma, and
therefore also in the morbidly obese the diagnosis of asthma should also be based on pulmo-
nary function testing.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The prevalence and incidence of asthma has increased over
the recent decades.1,2 Besides an improved awareness of
the disease, there are several other explanations for the
increased asthma prevalence, such as air pollution, expo-
sure to tobacco smoke, change in diet and obesity.2
Recently, the incidence and prevalence of obesity have
increased concurrently with the incidence and prevalence
of asthma, suggesting a possible link between obesity and
asthma.3,4
International guidelines advise that asthma diagnosis
should be based on both the presence of symptoms and
objective measurements of variable airflow obstruction or
bronchial hyperresponsiveness (BHR).1 However, in daily
practice spirometry or provocation tests are not always
performed, and the diagnosis of asthma is mainly based on
symptoms.5 Since obese patients report more dyspnea and
asthma-like symptoms than non-obese patients,6,7 it might
be that they unjustified get labeled as asthma (over-
diagnosis) without performing adequate diagnostics. In-
evitably, any misdiagnosis may lead to inappropriate
treatment,5 with increased risk of side-effects and increased
costs.8
Many epidemiological studies concerning obesity and
asthma have used physician-diagnosed asthma without
confirmation by pulmonary function tests. This implies
reasonable doubt as to the correctness of the diagnosis.
Multiple studies report that asthma could be excluded after
extensive testing in 30% of physician-diagnosed asthma,9e11
even after stopping with asthma medication.12 On the
other hand, missing the diagnosis of asthma in this popu-
lation is also an important issue. Impaired dyspnea
perception is especially thought to play a role in severe
asthma,13,14 and poor perception of airflow obstruction
may lead to under-treatment of asthma.15,16 All the recent
studies concerning overdiagnosis of asthma in the
obese,11,12,17 initially used selected subjects with asthma,
and therefore did not take into account obese patients in
which asthma was not detected. Therefore, the informa-
tion about underdiagnosis of asthma in the obese is
incomplete.
The hypothesis of the present study was that underdi-
agnosis of asthma is also present in the morbidly obese. We
therefore used an extensive diagnostic algorithm to inves-
tigate whether in addition to overdiagnosis also underdi-
agnosis of asthma is present in a morbidly obese cohort,
which was recruited from a pre-operative screening pro-
gram for bariatric surgery.Methods
Study population
The subjects included in this study were patients who un-
derwent pre-operative screening before bariatric surgery in
the Sint Franciscus Gasthuis in Rotterdam, the Netherlands
from September 2009 to April 2011. Eligibility criteria for
bariatric surgery were: age between 18 and 60 years old,
body mass index (BMI)  35 kg/m2. We excluded people
who (a) were older than 50 years of age or; (b) had a history
of smoking more than 10 cigarettes a day, or were currently
smoking more than 10 cigarettes a day (with the aim to
decrease the risk of including subjects with chronic
obstructive pulmonary disease [COPD]); (c) were taking oral
corticosteroid therapy; (d) had an asthma exacerbation
four weeks before screening; (e) were unable to perform
pulmonary function tests; or (f) had pulmonary disease
other than asthma.
We aimed for 40 subjects with, and 40 subjects without
asthma, as this study is a part of a longitudinal study. All
subjects underwent baseline physical examinations
including routine assessment of anthropometry, blood
pressure and blood samples. Waist circumference was
measured directly to the body surface midway between the
lower rib margin and the ileac crest. Fat free mass and fat
weight (in kg and % body weight) were measured using bio-
electrical impedance analysis (Bodystat 1500, Bodystat Ltd,
British Isles).18
All subjects gave written informed consent and the local
ethics committee (Toetsingscommissie Wetenschappenlijk
Onderzoek Rotterdam e.o.) approved the study protocol
(Netherlands Trial Register 3204).Pulmonary function tests
All subjects underwent lung function testing for the pres-
ence of reversible airflow obstruction as part of the
screening protocol before bariatric surgery. Spirometry was
performed with Vmax spirometer (Vmax SensorMedics Via-
sys, type Encore 20/22/229/62 Encore, Cardinal Health,
USA) before and after 400 mg of inhaled salbutamol, ac-
cording to the American Thoracic Society/European Respi-
ratory Society guidelines.19 All values obtained were
related to height, age and gender and expressed as per-
centage of their predicted value (reference ERS 199320).
The pulmonary function results are prebronchodilator
values unless otherwise specified.
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for a second visit for further lung function evaluation.
Again, if applicable, subjects were asked not to use long-
acting b-agonists for 48 h, short-acting b-agonists for
8 h and antihistamines or antileukotriene medication
72 h before lung function testing. Subjects who were using
inhaled corticosteroids (ICS), were asked to voluntarily
discontinue this. Daily symptom diary and daily peak flow
rates were used to optimally screen asthma control. Sub-
jects were permitted to use short-acting bronchodilators as
rescue medication. After six weeks they returned for their
second visit, during which exhaled Nitric Oxide (FeNO)
(Niox mino Aerocrine, Sweden),21 impulse oscillometry
(IOS) (Masterscreen IOS system, Erich Jaeger Co., Wu¨rz-
burg, Germany), diffusion capacity (intrabreath method,
corrected for hemoglobin and alveolar volume)22 and
methacholine provocation testing (five breath dosimeter
method)23,24 were performed. Bronchial responsiveness to
methacholine was expressed as the provocative dose of
methacholine inducing a 20% fall in FEV1 (PD20). A
PD20 < 1.8 mg was considered as a positive provocation
test. If the methacholine provocation test was negative, a
second provocation test was performed six weeks later.
Subjects who refused to stop the ICS, or subjects who had
exacerbations of asthma symptoms during the 12 weeks of
discontinuing their medication, underwent provocation
testing while using ICS (Fig. 2a, supplementary files).
Definition of asthma
Asthma was defined according to GINA guidelines1 as both
the presence of symptoms and either an increase of 12%
and 200 ml in FEV1 after salbutamol, or a positive provo-
cation test. Physician diagnosis of asthma was scored as a
positive reaction to the following question “Did a medical
doctor ever told you that you have asthma?”. Patients with
a physician diagnosis of asthma and fulfilling the criteria of
asthma were defined as having a correct asthma diagnosis.
Those without physician diagnosed asthma, but who ful-
filled the criteria for asthma were defined as under-
diagnosed. The subjects with physician-diagnosed asthma,
but who not fulfilled the criteria of asthma after stopping
inhaled corticosteroids for more than 6 weeks were defined
as overdiagnosed. Patients without airway reversibility and
a negative provocation test formed the control group
(Fig. 2b, supplementary files).
Questionnaires
Asthma symptoms were assessed by the mini Asthma
Quality of Life Questionnaire (AQLQ)25 and the Asthma
Control Questionnaire (ACQ)26 to assess asthma complaints.
The Epworth Sleepiness Scale27 questionnaire was used to
assess OSAS, and the GERD-Questionnaire for gastro-
esophageal reflux disease (GERD).28 The average of 7 days
with an activity meter was used to determine the total
number of steps taken a day, as a measure of activity.
Atopy
Atopic status was assessed with skin-prick tests (SPT) with a
battery of commonaeroallergens: house-dustmite; dog, cat,and horse dander; Aspergillus fumigatus; mugwort; and
birch and grass pollen (Vivodiagnost; ALK Benelux BV, Gro-
ningen, The Netherlands). SPT cutaneous response was
compared with a histamine-positive control and a saline
solutionenegative control. A positive resultwas defined as at
least one response with a wheal diameter 3 mm after
15 min. Total IgE and specific plasma IgE were determined
with a solid-phase two-step chemiluminescent immunoassay
on the Immulite 2000 (Siemens, Los Angeles, CA). A positive
inhalation screen was defined as at least one increased
amount of specific IgE for fungus, house-dust mite, cat, dog,
grass, birch or herbs.
Laboratory
Blood cell counts and 5-part leukocyte differentiation were
determined automatically using LH750 analyzers (Beckman
Coulter Miami, FL, USA). CRP was measured using LX 20 and
DxC analyzers (Beckman Coulter, Miami, FL, USA). Vitamin
D (was determined by RIA or chemiluminescence (LIA) on
Liason analyzers (DiaSorin, Stillwater, MN, USA).
Statistical analyses
Underdiagnosis of asthma subjects were consecutively
compared with correctly diagnosed asthma, overdiagnosis of
asthma and controls. Unless indicated otherwise, all data are
expressed as median (minemax) for scale variables or per-
centage for categorical variables. Unadjusted between
groups comparisons were performed using Mann Withney U
test, Chi square or Fisher exact test as appropriate. Cohen’s
Kappa coefficient was calculated as a measure of inter-rater
agreement. IgE and FeNOwere log transformed for statistical
purposes. All analyses were performed using SPSS 18.0 soft-
ware (SPSS Inc., Chicago, Illinois, USA). Results were evalu-
ated at 95% confidence interval at a two-sided significance
threshold of p < 0.005 (Bonferroni correction for multiple
testing).
Results
Demographics
In total 473 patients were screened. 220 subjects met the in-
clusion criteria, and 86 subjects agreed to participate in the
study. The most frequently reported reasons for refusing
participationwere“no time foradditional appointmentsdue to
work” and “distance to hospital too far”. The 136 subjectswho
declined consent did not significantly differ in demographic
characteristics from the participants (BMI, weight, abdominal
circumference, age or gender; data not shown) (Fig. 1).
From the 86 assessed patients, 32 patients had
physician-diagnosed asthma. However, using the diagnostic
algorithm, asthma could be excluded based on the absence
of reversibility in FEV1 or negative provocation test in 13 of
these subjects (41%, 95% CI [0.24e0.50]) (overdiagnosis). In
contrast, when analyzing the 54 patients without physician-
diagnosed asthma, we found that 17 patients (31%, 95% CI
[0.20e0.46]) had symptoms and a reversible airflow
obstruction or airway hyperreactivity (underdiagnosis). This
Pre-operative screening before 
bariatric surgery
n = 437
Participants enrolled in study
n = 86
Excluded n= 215
Age > 50 years n=95
> 10 PY, or smoking >10 cigarettes a day, n=90
Unable to perform lung function assessment n=18
Other pulmonary disease than asthma, n=11
Using oral steroids, n=1
Asthma excluded
Overdiagnosis
n=13
Physician diagnosed asthma
n= 32
No physician diagnosed 
asthma
n= 54
Met inclusion criteria
n = 222
Excluded n=136
Declined consent
Asthma confirmed
Correct diagnosis
n=19
Asthma confirmed
Underdiagnosis
n=17
Asthma excluded
Control
n=37
Asthma
N= 36
No asthma
N= 50
Figure 1 Selection of participants and study outcome.
Misdiagnosis of asthma 1359way, among the 86 assessed subjects, 36 true asthma pa-
tients were diagnosed and 50 true controls. Cohen’s Kappa
coefficient between physician diagnosed asthma and our
diagnosis of asthma was 0.251. Table 1 shows the baseline
characteristics of the four groups. There were no significant
differences in demographic characteristics between the
groups, especially not in age, body mass index or weight.
However, the subjects with underdiagnosis of asthma had a
significantly larger abdominal circumference than the
controls.
Symptoms and questionnaires
There were no differences in symptoms between the group
with an underdiagnosis of asthma and the correctly diag-
nosed asthma group or the overdiagnosis asthma group(Table 2). The underdiagnosis group trended toward having
more complaints of wheezing and coughing than the control
group. There was also a trend that the asthma control
questionnaire (ACQ) was better for the underdiagnosis group
compared to the correctly diagnosed asthma group. The ACQ
of the underdiagnosis group was comparable with the over-
diagnosis group, and significantly better than the controls.
The asthma quality of life questionnaire (AQLQ) was signifi-
cant worse for the underdiagnosis group, compared with the
controls, and comparable with the correctly diagnosis
asthma and overdiagnosis asthma groups.
Medication use
Eleven of the patients with correctly diagnosed asthma
were using ICS at the start of the study. Three refused to
Table 1 Demographics of study population.
Underdiagnosis
asthma N Z 17
Correct asthma
diagnosis N Z 19
Overdiagnosis
asthma N Z 13
Control N Z 37 p-Valuea p-Valueb p-Valuec
Gender (%female) 77% 79% 92% 78% 1.000 0.355 1.000
Ethnicity
(%non-Caucasian)
24% 11% 8% 14% 0.391 0.355 0.439
Age (years) 36 (19e49) 33 (24e48) 39 (19e50) 37 (18e50) 0.590 0.543 0.479
Weight (kg) 131 (111e240) 131 (101e191) 126 (99e157) 123 (94e199) 0.568 0.391 0.144
Body mass index
(kg/m2)
45.8 (38.7e74.8) 45.1 (38.4e63.8) 45.4 (37.4e53.8) 42.3 (35.6e60.0) 0.788 0.660 0.171
Abdominal
circumference (cm)
137 (118e165) 129 (112e158) 130 (109e142) 125 (98e200) 0.206 0.013 0.005
Bio-impedance
Fat free Mass 65.7 (47.8e100.5) 60.9 (50.3e94.8) 61.4 (50.9e72.6) 62.5 (47.2e83.9) 0.448 0.464 0.385
Fat weight (%) 50.9 (40.7e64.1) 52.8 (37.6e70.4) 51.6 (46.5e58.6) 50.2 (31.1e59.7) 0.499 0.568 0.578
Fat weight (kg) 68.5 (55.7e141.0) 69.1 (44.5e134.4) 64.0 (52.8e83.8) 59.2 (32.0e100.0) 0.934 0.754 0.057
Smoking status 0.865 0.932 0.236
%Never smoked 59% 53% 54% 78%
%Stopped smoking 18% 16% 23% 14%
%Current smoker 23% 31% 23% 8%
Pack years 0 (0e9) 0 (0e10) 0 (0e10) 0 (0e9) 0.589 0.764 0.119
Data are presented as median (minemax).
a p Value for comparison between underdiagnosis asthma and correct asthma diagnosis.
b p Value for comparison between underdiagnosis asthma and overdiagnosis asthma.
c p Value for comparison between underdiagnosis asthma and control.
Table 2 Symptoms, questionnaires, and medication use.
Underdiagnosis
asthma N Z 17
Correct asthma
diagnosis N Z 19
Overdiagnosis
asthma N Z 13
Control
N Z 37
p-Valuea p-Valueb p-Valuec
Symptoms previous 12 months
Dyspnea at rest 17.6% 47.4% 15.4% 5.4% 0.083 1.000 0.311
Dyspnea on exertion 94.1% 89.5% 84.6% 81.1% 1.000 0.565 0.411
Dyspnea at night 11.8% 42.1% 30.8% 5.4% 0.065 0.360 0.582
Wheezing 47.1% 84.2% 76.9% 18.9% 0.033 0.141 0.032
Coughing 52.9% 73.7% 76.9% 18.9% 0.299 0.259 0.011
Asthma control questionnaired 0.9 (0.4e1.9) 1.4 (0.3e2.9) 0.8 (0e2.9) 0.3 (0e2.3) 0.021 0.563 <0.001
Asthma quality of life
questionnaire (total)e
6.1 (5.2e6.8) 5.3 (3.7e7.0) 5.5 (3.7e6.6) 6.7 (4.9e7.0) 0.016 0.069 0.002
AQLQ symptoms 5.8 (4.6e6.6) 4.6 (3.6e7.0) 5.5 (3.4e6.8) 6.6 (3.8e7.0) 0.045 0.202 <0.001
AQLQ activities 5.8 (3.5e6.8) 5.3 (1.8e7.0) 5.4 (3.0e7.0) 7.0 (3.3e7.0) 0.641 0.505 0.001
AQLQ emotions 7.0 (5.7e7.0) 6.3 (4.3e7.0) 6.7 (5.0e7.0) 7.0 (6.3e7.0) 0.018 0.172 0.018
AQLQ environment 6.7 (4.0e7.0) 4.7 (2.0e7.0) 4.5 (3.0e7.0) 6.7 (3.0e7.0) 0.002 0.006 0.444
Medication use at inclusion study
Short acting bronchodilator 0% 74% 77% 0% <0.001 <0.001 1.000
Long acting bronchodilator 0% 11% 8% 0% 0487 0.433 1.000
Antileukotrienes 0% 0% 8% 0% 1.000 0.433 1.000
B2 sympaticomimetica/ICS 0% 32% 23% 0% 0.020 0.070 1.000
Inhaled corticosteroids 0% 32% 23% 0% 0.020 0.070 1.000
Antihistamines 12% 32% 15% 11% 0.236 1.000 1.000
Nasal corticosteroids 0% 26% 15% 8% 0.047 0.179 0.544
Data are presented as median (minemax)
AQLQ Z mini asthma quality of life questionnaire; ICS Z inhaled corticosteroid.
a p Value for comparison between underdiagnosis asthma and correct asthma diagnosis.
b p Value for comparison between underdiagnosis asthma and overdiagnosis asthma.
c p Value for comparison between underdiagnosis asthma and control.
d Scores of the asthma control questionnaire range from 0 to 6, with lower scores indicating better asthma control.
e Scores of the AQLQ range from 1 to 7, with higher scores indicating better asthma-specific quality of life.
1360 A. van Huisstede et al.
Misdiagnosis of asthma 1361stop the ICS. Of the eight subjects who withheld their ICS,
two had an increase of asthma symptoms and resumed their
ICS. Also, three asthmatics without ICS before the start of
the study had an increase in asthma symptoms, and started
with ICS. In the overdiagnosed subjects, three were using
ICS at the start of the study, and all agreed to withhold
their ICS, without any change in symptoms.
Lung function parameters
A methacholine provocation test was not performed in two
of the underdiagnosed subjects, because of low FEV1
(n Z 1) and extreme obesity (BMI 71, n Z 1), and once in
the correct diagnosis asthma group because of poor lung
function technique. All three, however, had reversible
airway obstruction (delta FEV1  12%). 18 correctly diag-
nosed asthmatics had a positive provocation test, of which
8 also had reversible airway obstruction. 11 of the under-
diagnosed subjects had a positive provocation test, of
which only one also had reversible airway obstruction. The
diagnosis asthma was only based on reversibility, with a
negative provocation test in 4 underdiagnosed asthmatics.
There was no difference in lung volumes, FeNO or
diffusion capacity between the investigated groups. Among
the parameters of the IOS there was a trend that R5 and Fres
were higher in the underdiagnosed group compared to the
control group (Table 3).
Blood parameters
With regard to the laboratory parameters (Table 3), there
was no difference between the investigated groups.
Allergy, activity and comorbidity
There was no difference in allergy, reflected in either a
positive inhalation screen or a positive SPT, or rhinitis be-
tween the investigated groups (Table 3).
To assess the activity of the subjects, a step-counter was
used, which showed no significant differences between the
investigated groups. There were also no differences in
comorbidities, such as obstructive sleep apnea syndrome
(Epworth Sleepiness Scale) or reflux (GERD-questionnaire)
(both Table 3), or the presence of the metabolic syndrome.Discussion
We found that after discontinuation of inhaled corticoste-
roids and extensive lung function and provocation tests,
misdiagnosis of asthma was present in our morbidly obese
cohort. In addition to confirming previous reports on over-
diagnosis of asthma, importantly we also found that a
substantial proportion of morbidly obese asthma patients
were underdiagnosed. This indicates that in the morbidly
obese, the diagnosis of asthma cannot be made on asthma-
like symptoms alone, and lung function testing is an
essential part of the diagnosis of asthma, as confirmed with
a low Cohen’s kappa coefficient for physicians and our
diagnosis of asthma.This is, to our knowledge, the first study investigating
both overdiagnosis and underdiagnosis of asthma in an
obese cohort. Furthermore, we have used an extensive
diagnostic algorithm to confirm or exclude asthma. In
addition, we have also looked at co-morbidities such as
reflux and OSAS, which are abundant in the obese and are
known to influence asthma. Moreover, also cofactors such
as immobility and allergy were taken into account.
We confirm previous reports showing that overdiagnosis
of asthma is present in the morbidly obese,11,12,17 although
Aaron found that overdiagnosis of asthma was overall no
more likely to occur among obese individuals than among
non-obese individuals. However, in studies so far concern-
ing overdiagnosis of asthma, assessment of underdiagnosis
was not part of these studies. We also found underdiagnosis
of asthma in our cohort of morbidly obese subjects, a
previously overlooked problem.
In the present study symptoms turned out to be unreli-
able for an adequate diagnosis of asthma. Subjects with an
overdiagnosis of asthma reported asthma-like symptoms,
which explain the overdiagnosis. Interestingly, patients
who were underdiagnosed for asthma also had symptoms.
The reason why they did not receive a previous diagnosis of
asthma is not clear, but may be explained by two factors.
First, this discrepancy might be due to self-misperception;
the patients themselves did not relate their symptoms to
respiratory disease but rather to obesity and did not con-
tact a physician for these complaints. A second possibility
could be that they did contact a physician for dyspnea, but
these discomforts were attributed to obesity by the physi-
cian (physician misperception). Self-misperception of res-
piratory symptoms is probably the most relevant factor,29
and might be partly explained by worse perception of
dyspnea. Unfortunately, no data were available on previous
visits to a physician because of respiratory symptoms.
Interestingly, especially R5 e a marker of both central
and distal airways obstruction e was particularly high in the
underdiagnosed subjects. The underdiagnosed subjects, in
particular, had a large abdominal circumference in our
study. Therefore, central obesity may lead to obstruction of
the peripheral airways, which may be more related to poor
perception of dyspnea than proximal airway obstruction.
This suggests that it is not the amount of fat, but the
location of the fat, which influences asthma perceptions,
which is also supported by a study from Lessard.30 Similar to
the symptoms, the inappropriate use of inhaled medication
was high in the overdiagnosis asthma group. This may result
in serious side effects and, moreover, contributes to the
economic burden of asthma. The symptoms could not be
explained by a restriction or a low diffusion capacity. There
was no difference in smoking status, furthermore as result
of the exclusion criteria, the median number of pack years
was nihil, so smoking is unlikely to be a contribution factor.
There was no difference in co-morbidities such as allergy,
GERD, OSAS or activity between asthmatics and controls,
and therefore these factors do not seem to play a role in
asthma in the obese.
There were few differences between the under-
diagnosed and the overdiagnosed subjects. However, many
of the overdiagnosed subjects had rhinitis, which can cause
dyspnea perception.31 Furthermore, the overdiagnosed
scored low for the AQLQ, especially in the environment
Table 3 Pulmonary function, laboratory and co morbidity.
Underdiagnosis
asthma N Z 17
Correct asthma
diagnosis N Z 19
Overdiagnosis
asthma N Z 13
Control
N Z 37
p-Valuec p-Valued p-Valuee
Spirometry
FEV1, pre (% predicted) 85 (62e99) 88 (66e119) 99 (84e125) 96 (73e120) 0.260 <0.001 0.001
FEV1, post (% predicted) 92 (72e118) 96 (74e118) 102 (90e129) 99 (75e124) 0.738 0.025 0.002
FVC, pre (% predicted) 93 (74e112) 100 (75e128) 108 (91e133) 102 (77e144) 0.154 0.004 0.019
FEV1/FVC, pre
(% predicted)
77 (63e92) 75 (66e86) 81 (74e87) 82 (66e93) 0.465 0.039 0.010
RV, post (% predicted)a 71 (39e117) 69 (39e126) 76 (48e118) 72 (33e96) 0.595 0.596 0.764
TLC, post (% predicted)a 94 (83e100) 100 (80e106) 97 (85e114) 94 (75e114) 0.104 0.180 0.920
FRC, post (% predicted)a 61 (40e87) 56 (47e95) 64 (51e88) 63 (41e85) 0.682 0.910 0.737
RV/TLC, post
(% predicted)a
19 (12e35) 24 (10e41) 24 (14e41) 25 (12e86) 0.289 0.176 0.146
FEF25-75, pre
(% predicted)
75 (33e119) 69 (38e111) 97 (64e118) 96 (49e135) 0.751 0.009 0.003
Reversibility FEV1 10 (6e20) 9 (1e20) 4 (7e9) 4 (2e11) 1.000 0.009 0.001
FeNO (bbp)b 16 (5e89) 14 (8e45) 11 (3e18) 16 (5e47) 0.968 0.087 0.783
Diffusion capacity
(% predicted)
97 (83e133) 95 (69e130) 97 (69e134) 95 (75e132) 0.333 0.769 0.132
IOS
R5 (kPa/sec) 0.69
(0.44e1.06)
0.76
(0.42e1.39)
0.59
(0.44e0.85)
0.56
(0.17e0.97)
0.738 0.139 0.008
R20 (kPa/sec) 0.45
(0.30e0.76)
0.40
(0.27e1.03)
0.71
(0.26e0.68)
0.42
(0.18e0.67)
0.317 0.139 0.143
X5 (kPa/sec) 0.24
(0.42-0.16)
0.29
(0.87-0.11)
0.24
(0.40-0.16)
0.19
(0.43-0.08)
0.615 0.999 0.049
Fres (Hz) 22.0
(16.0e24.9)
22.8
(10.5e30.3)
18.7
(14.0e23.2)
16.3
(8.4e28.7)
0.738 0.139 0.008
Peripheral blood count
Leukocytes (109/L) 8.5 (5e12) 8.9 (6e13) 7.1 (6e12) 7.4 (5e11) 0.477 0.288 0.084
Neutrophils (%) 65 (50e72) 61 (45e72) 59 (47e70) 59 (46e69) 0.555 0.166 0.099
Lymphocytes (%) 27 (15e38) 28 (17e45) 33 (20e43) 31 (23e47) 0.835 0.112 0.095
Monocytes (%) 6.61
(4.66e8.50)
6.74
(5.55e12.76)
6.45
(4.00e9.00)
6.41
(4.00e13.43)
0.795 0.945 0.840
Eosinophils (%) 2.49
(0.54e9.09)
2.35
(0.47e8.00)
2.00
(1.00e4.00)
2.04
(0.40e7.85)
0.887 0.835 0.437
Basophils (%) 0.38
(0.00e1.00)
0.52
(0.00e1.19)
0.13
(0.00e1.51)
0.50
(0.00e2.45)
0.339 0.560 0.202
IgE (kU/L)b 105 (7e3419) 202 (11e1838) 66.4 (10e273) 71.6
(1.5e587)
0.520 0.072 0.430
CRP (mg/L) 7(1e28) 8 (3e25) 7 (5e21) 9 (1e24) 1.000 0.724 0.858
Vitamin D (nmol/L) 27 (11e78) 37 (12e89) 39 (18e62) 41 (10e83) 0.438 0.232 0.205
Rhinitis 41% 84% 62% 30% 0.014 0.462 0.407
Positive inhalation screen 63% 73% 39% 38% 0.478 0.272 0.098
Skin prick test
(% 1 positive wheal)
47% 74% 36% 32% 0.160 0.701 0.334
Epworth sleepiness scale 2 (0e7) 3 (0e8) 2 (0e9) 2 (0e15) 0.351 0.770 0.786
GERD-questionnaire 6 (4e10) 7 (4e12) 6 (2e10) 6.5 (3e14) 0.074 0.146 0.022
Metabolic syndrome 53% 61% 75% 40% 0.738 0.273 0.335
Steps a day 4360
(1309e10,840)
5642
(2156e12,176)
6197
(4456e10,083)
4730
(2061e11,705)
0.415 0.096 0.829
Data are presented as median (minemax).
FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital capacity; RV Z residual volume; TLC Z total lung capacity;
FRCZ functional residual capacity; ERVZ expiratory reserve volume; FEF25e75Z Forced expiratory flow at 25% point to the 75% point
of Forced Vital Capacity; FeNO Z exhaled nitric oxide; Diffision capacity Z kCO.
a Because of weight limitations (<150 kg) of bodybox different numbers; underdiagnosis asthma n Z 11, correct asthma diagnosis
n Z 10, overdiagnosis asthma n Z 10, control n Z 26.
b Log transformed for statistical purposes.
c p Value for comparison between underdiagnosis asthma and correct asthma diagnosis.
d p Value for comparison between underdiagnosis asthma and overdiagnosis asthma.
e p Value for comparison between underdiagnosis asthma and control.
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stimuli are scored. However, by definition, all over-
diagnosed had a negative provocation test. This reduced
QOL in morbidly obese overdiagnosed asthma subjects was
also found by Scott et al.11 These data suggest that the
discrepancy between pulmonary function test and the
AQLQ, might in part be explained by rhinitis.
There are several limitations to our study. Only 39% of
potentially eligible subjects agreed to participate. So a
volunteer bias could have influenced the study results. The
large proportion of declines is most probably due to the fact
that this study is a part of a longitudinal study. Another
effect of this study being a part of another study, is the fact
that we aimed for 40 subjects with and 40 subjects without
asthma and that inclusion of the latter group went faster,
so subjects were not enrolled in a consecutive order. So the
prevalence of physician diagnosed asthma in our study
cohort is biased, and therefore also the prevalence of
under- or overdiagnosis of asthma is biased. Importantly,
however, there were no differences in patient de-
mographics between the subjects who declined consent
and those who participated. Since a lean control group was
not part of the study, it is not clear whether underdiagnosis
is more prevalent among the obese compared to a lean
cohort. The selection of subjects willing to undergo bar-
iatric surgery could also have led to a selection bias. And
finally, the small group of misdiagnosed subjects (either
over- or underdiagnosis) could have given us power prob-
lems to find differences in subgroup analysis.
In summary, both overdiagnosis as well as underdiagnosis
of asthma occurs in the morbidly obese. A diagnosis of
asthma based on symptoms alone is unreliable in the
morbidly obese, and pulmonary function testing is an
essential part of the diagnosis of asthma in the morbidly
obese. As a result of the most likely high prevalence, po-
tential health risk and the high economic burden of misdi-
agnosis, characterization of these patients is important.
Further research aiming at the effects of weight reduction
on quality of life and symptoms, not only in asthmatics but
also in the overdiagnosed can provide valuable further in-
sights into this interesting problem.
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